TLP Group’s Alexion Pharmaceuticals ALXN Stock Holding History

TLP Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-150	Closed	-$21K	–	765
2017 Q3	$21K	Buy	+150	New	+$20.4K	0.01%	270
2016 Q3	–	Sell	-4,921	Closed	-$575K	–	423
2016 Q2	$575K	Buy	+4,921	New	+$698K	0.39%	71

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TLP Group's ALXN Position: Q4 2017 in Review

TLP Group sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 150 shares — an estimated $21K sold.

TLP Group first reported a position in ALXN in Q2 2016 and held it in 2 quarters. The position peaked at $575K in Q2 2016. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

TLP Group reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
TLP Group sold 150 Alexion Pharmaceuticals shares in Q4 2017, an estimated $21K.
TLP Group first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 2 quarters.
TLP Group's Alexion Pharmaceuticals position peaked at $575K in Q2 2016.
587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on TLP Group's 13F filing for Q4 2017, filed 14 Feb 2018.